Literature DB >> 10878487

Humoral and cellular autoimmunity in autoimmune bullous skin disorders.

M Hertl1.   

Abstract

Autoimmune bullous skin diseases, such as pemphigus vulgaris (PV) and bullous pemphigoid (BP), are severe, frequently life-threatening skin disorders. Immunologically, they are characterized by the presence of serum autoantibodies (auto-Ab) targeting distinct adhesion molecules of the epidermis or dermoepidermal basement membrane zone. Antibody (Ab) binding interferes with the adhesive function of these molecules, leading to detachment and subsequently blister formation. PV is the classical example of an Ab-mediated autoimmune disease affecting epidermal adhesion. Auto-Ab against the desmosomal adhesion molecule, desmoglein 3 (Dsg3), are critical in the pathogenesis of this disease, since the transfer of serum IgG Ab reactive with Dsg3 into newborn mice induces a bullous skin disease resembling PV. Autoreactive T cell responses to Dsg3 may be critical in the pathogenesis of PV because: (1) Ab production generally requires T cell help; (2) the involvement of CD4+ T lymphocytes in PV has been suggested by the strong association with distinct HLA class II alleles, and (3) T cell recognition of epitopes of Dsg3 may be crucial for the initiation and perpetuation of the production of Dsg3-specific auto-Ab by B cells. In PV and BP, autoreactive CD4+ T cells recognize distinct epitopes of the extracellular portions of Dsg3 and BP180 [BP antigen 2 (BPAG2) or type XVII collagen], respectively, and produce preferentially T helper type 2 (TH2) cytokines. Auto-Ab of the TH2-dependent IgG4 subtype are preferentially seen in the active stages of both PV and BP, while auto-Ab of the TH1-dependent IgG1 subclass are predominant during the chronic course of these disorders. These observations suggest that autoreactive TH2 cells may provide targets to specifically modulate the T cell-dependent production of pathogenic auto-Ab in these disorders. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2000        PMID: 10878487     DOI: 10.1159/000024364

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  9 in total

1.  The association of bullous pemphigoid and ulcerative colitis.

Authors:  Lisbeth Selby; Fernando De Castro; Willem J S De Villiers
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 2.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

Review 3.  T cell control in autoimmune bullous skin disorders.

Authors:  Michael Hertl; Rüdiger Eming; Christian Veldman
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

4.  T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.

Authors:  W J Pickford; V Gudi; A M Haggart; B J Lewis; R Herriot; R N Barker; A D Ormerod
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Interleukin-16 expression and release in bullous pemphigoid.

Authors:  A Frezzolini; G Cianchini; M Ruffelli; S Cadoni; P Puddu; O De Pità
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

6.  Coagulation activation in autoimmune bullous diseases.

Authors:  A V Marzano; A Tedeschi; D Spinelli; D Fanoni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

7.  Immunogenetic mechanisms for the coexistence of organ-specific and systemic autoimmune diseases.

Authors:  Masha Fridkis-Hareli
Journal:  J Autoimmune Dis       Date:  2008-02-15

8.  Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a preliminary study.

Authors:  Jixin Xue; Wenting Su; Zhiwei Chen; Youhui Ke; Xiaojing Du; Qiaochu Zhou
Journal:  Mediators Inflamm       Date:  2014-05-11       Impact factor: 4.711

9.  ST18 Enhances PV-IgG-Induced Loss of Keratinocyte Cohesion in Parallel to Increased ERK Activation.

Authors:  Mariya Y Radeva; Elias Walter; Ramona Alexandra Stach; Amir S Yazdi; Nicolas Schlegel; Ofer Sarig; Eli Sprecher; Jens Waschke
Journal:  Front Immunol       Date:  2019-04-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.